PROSPECTS OF APPLICATION OF PECTIN MODIFICATIONS IN THE COMPLEX MEDICAMENT THERAPY OF COLORECTAL CANCER

Golotiuk V. V.

LITERATURE REVIEWS

Scentific article

Colorectal cancer is one of the most common cancer globally. It occupy the fourth place in the structure of total cancer incidence. The basic treatment for colon cancer is surgery combined with chemotherapy or radiotherapy. Usually chemotherapy is provided by injection route. Alternative to the usual chemotherapy might be oral intake of chemotherapeutic agents. In this way can be achieved the reduce of drug dose, systemic side effects and increased efficiency. In general, 5 technologies for the specific delivery of drugs to the colon have been developed. All of them have a common concept that involves the use of physiological features of the gastrointestinal tract to provide activation and release of drugs to achieve colon. Among them: azo-polymer system, pH, pressure- and time-dependent systems, as well as delivery systems based on the activity of the colon microflora. Pectin can be used as colon-specific drug delivery agent, because colonic microflora can selectively digest it. So this leads to the prevention of drug release in the upper gastrointestinal tract. Unlike insoluble cellulose fibers, it undergoes almost 100% fermentation in the colon, leading to the formation of short-chain fatty acids, which are the main source of energy for colon cysts. In addition, short-chain fatty acids can suppress proliferation and promote tumor cell apoptosis in vitro and in vivo, and because of lowering the pH of the colon, they reduce the formation of secondary bile salts, impede the activity of 7-α-dehydroxylase, and reduce the solubility of free bile acid, showing account of the indicated properties anti-carcinogenic effect. Therefore pectin can be considered not only as drug carrier but also as therapeutic agent for use in the prevention and acting against colorectal cancer. The pectin-based matrices are developed in the form of a unit dose, as well as in a multi-dosage form: granules, pills, microparticles. To prevent the premature release of drugs from the pectin matrix in the upper gastrointestinal tract, the researchers were subjected to the last transverse coupling of di- and multivalent cations, coaccessing with an oppositely charged electrolyte, mixing with a viscous polymer and/or calcium salt, or coated by pH-resistant and weakly soluble polymer. Pectin, in combination with a crosslinking agents or polymers, can be used on the nucleus of the drug surface as a suppressive releasing membrane in the form of a film or applied by compression technology. In particular, a multi-layer coating on the core of the drug may be used, with the layers having different chemical composition to slow down/modulate the release of drugs in various locations of the upper gastrointestinal tract. Currently many researchers are trying to create a pectin dosage form for the delivery of drugs with delayed releasing effect. Gelatin, alginate and xyloglucan are just some of the polymers used in the formulation of pectin delivery systems. Thus, the analysis of the current literature data determined that further in-depth study of the pectin properties and an assessment of the link between its structure and capabilities in the aspect of creating a colon-specific drug delivery system are relevant and promising. The combined efficacy of pectin as a drug and/or therapeutic enhancer in delivering colon-specific anti-cancer drugs requires extensive testing in the clinic to confirm it. Creating a pectin dosage form of drug delivery to the colon, acting exclusively and precisely at the site of colorectal cancer is a challenge for pharmacists and oncologists.

pectin, colon cancer, treatment, chemotherapy

1. Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS Pharm Sci Tech. 2015;16(4):731-41.
2. Beloqui A, Coco R, Memvanga PB, Ucakar B, des Rieux A, Préat V. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm. 2014 Oct 1;473(1-2):203-12.
3. Chaurasia M, Chourasia MK, Jain NK, Jain A, Soni V, Gupta Y, et al. Methotrexate bearing calcium pectinate microspheres: a platform to achieve colon-specific drug release. Curr Drug Deliv. 2008 Jul;5(3):215-9.
4. Cheewatanakornkool K, Niratisai S, Manchun S, Dass CR, Sriamornsak P. Thiolated pectin-doxorubicin conjugates: Synthesis, characterization and anticancer activity studies. Carbohydr Polym. 2017 Oct 15;174:493-506.
5. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003;6(1):33-66.
6. Farkouh A, Scheithauer W, Buchner P, Georgopoulos A, Schueller J, Gruenberger B, et al. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab. Anticancer Res. 2014 Jul;34(7):3669-73.
7. Gazzaniga A, Maroni A, Sangalli ME, Zema L. Time-controlled oral delivery systems for colon targeting. Expert Opin Drug Deliv. 2006 Sep;3:583-97.
8. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344:1788-91.
9. Henaine AM, Chahine G, Salameh P, Elias E, Massoud M, Hartmann D, et al. Management of metastatic colorectal cancer: Current Treatments and New Therapies. J Med Liban. 2015 Oct-Dec;63(4):218-27.
10. Itoh K, Yahaba M, Takahashi A, Tsuruya R, Miyazaki S, Dairaku M, et al. In situ gelling xyloglucan/pectin formulations for oral sustained drug delivery. Int J Pharm. 2008 May 22;356(1-2):95-101.
11. Jain A, Gupta Y, Jain SK. Potential of calcium pectinate beads for target specific drug release to colon. J Drug Targeting. 2007;15(4):285-94.
12. Jain SK, Jain A. Target-specific drug release to the colon. Expert Opin Drug Deliv. 2008;5(5):483-98.
13. Komatsu Y, Harada K, Fukushima H, Yuki S. New molecular targeting drugs for metastatic colorectal cancer. Nihon Rinsho. 2014;72(1):120-6.
14. Kumar P, Mishra B. Colon targeted drug delivery systems – an overview. Curr Drug Deliv. 2008;5(3):186-98.
15. Liu J, Zhang L, Jia Y, Hu W, Zhang J, Jiang H. Preparation and evaluation of pectin-based colon-specific pulsatile capsule in vitro and in vivo. Arch Pharm Res. 2012 Nov;35(11):1927-34.
16. Liu Y, Zhou H. Budesonide-loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro/in vivo evaluation. Int J Mol Sci. 2015;16(2):2693-704.
17. Lu WQ, Wang F, Liu HY. Influence of oxaliplatin combined with LCP on proliferation and apoptosis of colon cancer cell line HT29. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16(1):84-8.
18. Maestrelli F, Cirri M, Corti G, Mennini N, Mura P. Development of enteric-coated calcium pectinate microspheres intended for colonic drug delivery. Eur J Pharm Biopharm. 2008 Jun;69:508-18.
19. Midgley RS, Merrie A, Kerr DJ. Colorectal cancer: a multidisciplinary approach. Clinical gastroenterology and hepatology. 2005;60:421-30.
20. Nakahara S, Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev. 2007;26:605-10.
21. Prado SBRD, Ferreira GF, Harazono Y, Shiga TM, Raz A, Carpita NC, et al. Ripening-induced chemical modifications of papaya pectin inhibit cancer cell proliferation. Sci Rep. 2017 Nov 29;7(1):16564.
22. Saito D, Nakaji S, Fukuda S, Shimoyama T, Sakamoto J, Sugawara K. Comparison of the amount of pectin in the human terminal ileum with the amount of orally administered pectin. Nutrition. 2005 Sep;21:914-9.
23. Sakamoto J, Oba K, Matsui T, Kobayashi M. Efficacy of oral anticancer agents for colorectal cancer. Dis Colon Rectum. 2006 Oct;49:82-91.
24. Sanz-Garcia E, Grasselli J, Argiles G, Elez ME, Tabernero J. Current and advancing treatments for metastatic colorectal cancer. Expert Opin Biol Ther. 2016;16(1):93-110.
25. Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015;148(6):1244-60.
26. Szente V, Zelkó R. Site-specific drug delivery systems. I. Colon targeted delivery. Acta Pharm Hung. 2007;77(3):185-89.
27. Wei X, Sun N, Wu B, Yin C, Wu W. Sigmoidal release of indomethacin from pectin matrix tablets: Effect of in situ crosslinking by calcium cations. Int J Pharm. 2006 Aug 2;318:132-8.
28. Wikiera A, Irla M, Mika M. Health-promoting properties of pectin. Postepy Hig Med Dosw (Online). 2014;68:590-6.
29. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40:235-43.
30. Wong TW, Nurjaya S. Drug release property of chitosan-pectinate beads and its changes under the influence of microwave. Eur J Pharm Biopharm. 2008;69:176-88.
31. Wu B, Deng D, Lu Y, Wu W. Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. Eur J Pharm Biopharm. 2008 May;69:294-302.

«Bulletin of problems biology and medicine» Issue 1 Part 1 (142), 2018 year, 25-30 pages, index UDK 616-006.6+615.28+547.458.88

10.29254/2077-4214-2018-1-1-142-25-30